Disease · GO_0030168
platelet activation
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. platelet activation. Diseases, record GO_0030168. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/GO_0030168
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- platelet activation
- Open Targets ID
- GO_0030168
- Other names
- blood coagulation, platelet activation
- Highest stage of its drugs
- Phase 2, for 3 of its 4 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ASPIRIN | CHEMBL25 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PRASUGREL | CHEMBL1201772 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SOTAGLIFLOZIN | CHEMBL3039507 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| P2RY12 | P2Y purinoceptor 12 | 2 | Purinergic receptor P2Y12 antagonist | Phase 2 | https://conductscience.org/library/genes/64805 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| SLC5A1 | Sodium/glucose cotransporter 1 | 1 | Sodium/glucose cotransporter 1 inhibitor | Early phase 1 | https://conductscience.org/library/genes/6523 | Drugs and targets |
| SLC5A2 | Sodium/glucose cotransporter 2 | 1 | Sodium/glucose cotransporter 2 inhibitor | Early phase 1 | https://conductscience.org/library/genes/6524 | Drugs and targets |
Trials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00357968 | Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting | Phase 2 | 201 | 2010-08-09 | Coronary Artery Disease | CLOPIDOGREL, PRASUGREL | Its record names the disease | ClinicalTrials.gov |
| NCT03316534 | Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients | Phase 2 | 40 | HIV-infected Patients | ASPIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06933056 | Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs | Early phase 1 | 21 | Platelet Function and Reactivity Tests | SOTAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Prasugrel vs Clopidogrel: Number of Participants With Major Adverse Cardiac Events (MACE) During the First Maintenance Dose Phase | 2 of 102 | 1 of 99 | 201 | NCT00357968 | Trial comparisons |
Prasugrel vs Clopidogrel: Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the First Maintenance Dose Phase | 2 of 102 | 0 of 99 | 201 | NCT00357968 | Trial comparisons |
| Prasugrel vs Clopidogrel: Number of Hyporesponsive Participants at 6 Hours After the Loading Dose | 0 of 72 | 21 of 77 | 149 | NCT00357968 | Trial comparisons |
Clopidogrel vs Prasugrel: Number of Participants With Non-Coronary Artery Bypass Graft (CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding During the Crossover Maintenance Dose Phase | 0 of 53 | 0 of 55 | 108 | NCT00357968 | Trial comparisons |
| Clopidogrel vs Prasugrel: Number of Participants With Major Adverse Cardiac Events During the Crossover Maintenance Dose Phase | 1 of 53 | 0 of 55 | 108 | NCT00357968 | Trial comparisons |
| Prasugrel vs Clopidogrel: Number of Hyporesponsive Participants at the End of the First Maintenance Dose Phase | 1 of 40 | 7 of 46 | 86 | NCT00357968 | Trial comparisons |
| Clopidogrel vs Prasugrel: Number of Hyporesponsive Participants at the End of the Crossover Maintenance Dose Phase | 4 of 40 | 1 of 45 | 85 | NCT00357968 | Trial comparisons |
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/GO_0030168
GET https://conductscience.org/api/diseases/v1/GO_0030168/drugs